ANALGESIC AND MUSCLE RELAXANT CAPLETS TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

IBUPROFEN; METHOCARBAMOL

から入手可能:

TEVA CANADA LIMITED

ATCコード:

M03BA53

INN（国際名）:

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

投薬量:

200MG; 500MG

医薬品形態:

TABLET

構図:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

投与経路:

ORAL

パッケージ内のユニット:

18/40

処方タイプ:

OTC

治療領域:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

製品概要:

Active ingredient group (AIG) number: 0248961001; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2021-08-12

製品の特徴

1 | P a g e
PRODUCT MONOGRAPH
ANALGESIC & MUSCLE RELAXANT CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED
Date of Preparation:
30 Novopharm Court
January 8, 2013
Toronto, Canada
M1B 2K9
Control# 161025
2 | P a g e
TABLE OF CONTENTS
Clinical Pharmacology
..............................................................................................................................
3
Indications:
................................................................................................................................................
7
Contraindications
......................................................................................................................................
8
Warnings:
..................................................................................................................................................
8
Precautions
..............................................................................................................................................
12
Drug Interactions
....................................................................................................................................
13
Adverse Reactions
..................................................................................................................................
15
Symptoms and Treatment of Overdose
...................................................................................................
17
Dosage and
Administration.....................................................................................................................
18
Pharmaceutical Information
....................................................................................................................
19
Composition:
...........................................................................................................................................
21
Availability of Dosage Forms
..........................